Accelerate Your Preclinical Research By InnoSer’s Innovative Methods.

Customizing in-vitro and in-vivo services for your success.

Recently At InnoSer

Towards Personalized Medicine By The Early Use Of Patient Data

by admin | July 9, 2020 | Blog, InnoSer offerings | 0 Comments

OPINION Traditional approaches to clinical drug development have created a critical gap between preclinical research and patient applications. Only the drugs that pass big clinical trials reach to the clinic, and a potentially heterogeneous group of patients end up...

Let’s reconsider your research – InnoSer contract breeding services

by admin | June 25, 2020 | InnoSer offerings, News | 0 Comments

COVID-19 restrictions brought extra challenges to breeding and maintaining colonies within academic facilities. If you are looking for a service provider resilient to today’s vulnerable environment, InnoSer is here to support you. Let’s put your research back on track...

InnoSer participates in the AACR annual meeting 2020

by admin | June 19, 2020 | Events, News | 0 Comments

InnoSer is proud to announce its participation in the annual meeting of the American Association for Cancer Research. As committed contributors to the preclinical oncology field, we look forward to interacting with the community throughout the event. We make this...

THERAPEUTIC AREAS

We Specialize In

InnoSer’s INNOVATIVE METHODS

Combining In-Vivo And In-Vitro

By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.

Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.

This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.

By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.

SERVICES OVERVIEW

GET IN TOUCH WITH US

Tell Us About Your Work

We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.

START A CONVERSATION

OUR CLIENTS ABOUT US

Academic And Commercial Expertise

“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”

Ad van de Gorp PhD, CEO Cythura Therapeutics

“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”

Joost van Bree, CEO Saillant Therapeutics

SEE ALL TESTIMONIALS



Phone

+32 (0)11 14 07 68



Headquarters

InnoSer België NV

Agoralaan A bis
3590 Diepenbeek
Belgium



Email

info@innoserlaboratories.com



Subsidiary

InnoSer Nederland BV

Zernikedreef 9
2333 CK Leiden
The Netherlands